XL-092
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for XL-092, covering 2026-03-20 to 2026-03-20. Get the full timeline:
Most recent: Clinical Trial Update: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) [Phase 2]